Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis ; volume:6 ; number:1 ; day:15 ; month:9 ; year:2008 ; pages:1-2 ; date:9.2008
Pediatric rheumatology ; 6, Heft 1 (15.9.2008), 1-2, 9.2008
- Creator
-
Susic, G.
Stojanovic, R.
Damjanov, N.
Vojinovic, J.
Vijatov, G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1546-0096-6-S1-P90
- URN
-
urn:nbn:de:101:1-2019062203330062289630
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Susic, G.
- Stojanovic, R.
- Damjanov, N.
- Vojinovic, J.
- Vijatov, G.
- SpringerLink (Online service)
Other Objects (12)
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Juvenile idiopathic arthritis treated with biological therapies
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Juvenile idiopathic arthritis treated with biological therapies
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry